Clinical trials: Cancer of the Esophagus
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Immunotherapy After Radiotherapy in Elderly ESCC
The incidence and mortality of esophageal squamous cell carcinoma are at the forefront in China.Most part of patients are elderly.
- Trial name
- TREE (NCT05791136)
- Testing
- Radiotherapy, Toripalimab
- Volunteers
- 30 people
- Sponsor
- The Central Hospital of Lishui City
Esophageal Cancer
Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer
This multicenter open labeled phase 2 trial examines the efficacy of a combination of Gemcitabine 1000 mg/m2 (30 min), Cisplatin 30 mg/m2 (90 min), Folinic Acid 200 mg/m2 (30 min) and 5-FU 750 mg/m2 (24h CI) all given day 1,8 q…
- Trial name
- CONKO-101 (NCT00759226)
- Testing
- Gemcitabine, Cisplatin, 5-FU
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- CONKO-Studiengruppe
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.
- Trial name
- NCT01368419
- Testing
- Endostar, Radiotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Lung Cancer, Gastric Cancer
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT07179692
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Esophageal Squamous Cell Carcinoma (ESCC)
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
Esophageal cancer is a high - incidence cancer type in China, characterized by high incidence, high mortality, and low survival rates.
- Trial name
- NCT06863831
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumors
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
The study evaluates safety of adavosertib in monotherapy, and in combination with 5-Fluorouracil (5-FU) alone or with 5-FU/cis-diamminedichloroplatinum (CDDP) in Japanese participants with solid tumor.
- Trial name
- NCT01047007
- Testing
- adavosertib 20 mg, 5-FU 1000 mg/m^2/day, CDDP
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Lung Cancer, Gastric Cancer
Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors
This is a Phase I（Ib）, open-label, single-arm clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of R01 administered orally as monotherapy twice daily (BID) in patients…
- Conditions
- Squamous Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07806500
- Testing
- R01
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Anjianxi Bio-Medical Technology Co., Ltd.
Colorectal Cancer, Gastric Cancer
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or…
- Conditions
- Colorectal Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- NCT04508140
- Testing
- Hepatic Biopsy, BO-112 with pembrolizumab
- Where
- 12 sites in Belgium, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Highlight Therapeutics
Esophageal Neoplasms, Stomach Neoplasms
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
- Trial name
- XAGastric (NCT00447330)
- Testing
- capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Anal Cancer, Anxiety Disorder
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may…
- Conditions
- Anal Cancer, Anxiety Disorder, Breast Cancer, Depression
- Trial name
- NCT00896467
- Testing
- questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Oscar Lambret
Cancer of the Head and Neck, Cancer of Lung
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
This study will aim to demonstrate that implementation of a rapid, multidisciplinary supportive care program for patients receiving chemoradiotherapy who are deemed to be at high risk for hospitalization based on real-time…
- Conditions
- Cancer of the Head and Neck, Cancer of Lung, Cancer of Esophagus, Cancer of Stomach
- Trial name
- RAMPART (NCT03102229)
- Testing
- Enhanced Supportive Care - Status Checks, Enhanced Supportive Care - Referrals
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Montefiore Medical Center
Oesophageal Cancer
Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer
This is a feasibility study testing the use of the Cytosponge™ device in patients with known oesophageal cancer treated with pre-operative or definitive chemoradiation.
- Trial name
- CYTOFLOC (NCT03529669)
- Testing
- Cytosponge™
- Where
- 11 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Esophagus Cancer, Lung Cancer
Imaging Study Compare 4DCT Image
The goal of this clinical research study is to learn about ways to possibly reduce scanning errors when using 4-dimensional computed tomography (4D CT) scans to check lung function in patients with esophageal or lung cancer.
- Trial name
- NCT01626001
- Testing
- 4D CT scans
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma, Progression to PD-1 Antibody
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.
- Trial name
- NCT04866381
- Testing
- SHR-6390, SHR-6390 + Camrelizumab (SHR-1210), Camrelizumab (SHR-1210) + SHR-1020
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Gastric Cancer
Diagnostic Performance Indicators in Upper GI Endoscopy:PROSPERO Study
Cancers of the upper gastro-intestinal tract, including esophagus (gullet), stomach and small bowel, are amongst the deadliest malignancies.
- Conditions
- Esophageal Cancer, Gastric Cancer, Barrett Esophagus, Gastric Atrophy
- Trial name
- PROSPERO (NCT04843397)
- Volunteers
- 1,000 people
- Sponsor
- University of Cambridge
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
Optional Sub-study to Intraoperative Imaging With ICG Registry
The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.
- Conditions
- Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
- Trial name
- NCT02651246
- Testing
- data collection
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Esophageal Squamous Cell Carcinoma (ESCC)
An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
Title: Observational Study on the Safety and Efficacy of Immunotherapy Combined with Concurrent Chemoradiotherapy in Elderly Patients with Esophageal Squamous Cell Carcinoma Study Purpose: This single-center, open-label…
- Trial name
- NCT07080437
- Testing
- Immunotherapy Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Three Gorges Hospital of Chongqing University
Esophageal Cancer
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
The purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer…
- Trial name
- PALEO (NCT06290505)
- Testing
- Durvalumab
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 54 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Esophageal Cancer
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00493025
- Testing
- cisplatin, gefitinib, paclitaxel
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.